Methyl (11aS)-1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo- [3′,4′:1,2]pyridin[3,4-b]-indol-2-substituted acetates: Synthesis and three-dimensional quantitative structure-activity relationship investigation as a class of novel vasodilators

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4715-4723

  Liu, Jiawang ^a   Zhao, Ming ^a   Cui, Guohui ^a   Zhang, Xiaoyi ^a   Wang, Jun ^a   Peng, Shiqi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,9 TETRAHYDRO 1H PYRIDO[3,4 B]INDOLE 3 CARBOXYLIC ACID; ACETIC ACID DERIVATIVE; DIMETHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 SUCCINATE; DIMETHYL 2 (2 (TERT BUTOXYCARBONYL) 2,3,4,9 TETRAHYDRO 1H PYRIDO[3,4 B] INDOLE 3 CARBOXAMIDO)PENTANEDIOATE; DIMETHYL 2 (2 TERT BUTOXYCARBONYL) 2,3,4,9 TETRAHYDRO 1H PYRIDO[3,4 B] INDOLE 3 CARBOXAMIDO)SUCCINATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4 B]INDOL 2 ACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 (INDOLE 3 YL METHYL)ACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 BENZYLACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 BUT 2 YLACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 HYDROXYL BENZYL)ACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 ISOBUTYLACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 ISOPROPYLACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO [3',4':1,2]PYRIDIN[3,4 B]INDOL 2 METHYLACETATE; METHYL 1,2,3,5,11,11A HEXAHYDRO 3,3 DIMETHYL 1 OXO 6H IMIDAZO[3',4':1,2]PYRIDIN[3,4 B]INDOL 2 SUBSTITUTED ACETATE; TERT BUTYL 3 (1 METHOXY 1 OXO 3 PHENYLPROPAN 2 YL CARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (1 METHOXY 1 OXOPROPAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (1 METHOXY 3 METHYL 1 OXOBUTAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE; TERT BUTYL 3 (1 METHOXY 3 METHYL 1 OXOPENTAN 2 YL CARBAMOYL 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE(9H) CARBOXYLATE; TERT BUTYL 3 (1 METHOXY 4 (METHYLTHIO) 1 OXOBUTAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (1 METHOXY 4 METHYL 1 OXOPENTAN 2 YLCARBAMOYL 3,4 DIHYDRO 1H PYRIDO[3,4B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (2 METHOXY 2 OXOETHYLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO [3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (2 METHOXY 2 OXOETHYLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (3 1H IMIDAZOLE 4 YL) 1 METHOXY 1 OXOPROPAN 2 YLCARBAMOYL) 3,4 DIHYDO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (3 HYDROXY 1 METHOXY 1 OXOBUTAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (3 HYDROXY 1 METHOXY 1 OXOPROPAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (4 AMINO 1 METHOXY 1,4 DIOXOBUTAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (5 AMINO 1 METHOXY 1,5 DIOXOPENTAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; TERT BUTYL 3 (5 GUANIDINO 1 METHOXY 1 OXOPENTAN 2 YLCARBAMOYL) 3,4 DIHYDRO 1H PYRIDO[3,4 B]INDOLE 2(9H) CARBOXYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT;

ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; VASODILATATION;

ACETATES; ANIMALS; CRYSTALLOGRAPHY, X-RAY; HYDROGEN; IMIDAZOLES; INDOLES; MALE; METHYLATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 49449104451     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800249j     Document Type: Article

References (24)

1. Johnsson, E.; Maddahi, A.; Wackenfors, A.; Edvinsson, L. Enhanced expression of contractile endothelin ETB receptors in rat coronary artery after organ culture. Eur. J. Pharmacol. 2008, 582, 94-101.
2. Stephen, Y.; Chan, A. C.; Loscalzo, J. Pathogenic mechanisms of pulmonary arterial hypertension. J. Mol. Cell. Cardiol. 2008, 44, 14-30.
3. Roux, S.; Loffler, B. M.; Gray, G. A.; Sprecher, U.; Clozel, M.; Clozel, J. P. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995, 37, 78-85.
4. Henriksson, M.; Stenman, E.; Edvinsson, L. Intracellular pathways involved in upregulation of vascular endothelin type B receptors in cerebral arteries of the rat. Stroke 2003, 34, 1479-1483.
5. Wackenfors, A.; Emilson, M.; Ingemansson, R.; Hortobagyi, T.; Szok, D.; Tajti, J.; Vecsei, L.; Edvinsson, L.; Malmsjo, M. Ischemic heart disease induces upregulation of endothelin receptor mRNA in human coronary arteries. Eur. J. Pharmacol. 2004, 484, 103-109.
6. Dagassan, P. H.; Breu, V.; Clozel, M.; Kunzli, A.; Vogt, P.; Turina, M.; Kiowski, W.; Clozel, J. P. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J. Cardiovasc. Pharmacol. 1996, 27, 147-153.
7. Beavo, J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 1995, 75, 725-748.
8. Conti, M.; Jin, S. L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 1999, 63, 1-38.
9. Houslay, M. D. Adaptation in cyclicAMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin. Cell Dev. Biol. 1998, 9, 161-167.
10. Francis, S. H.; Turko, I. V.; Corbin, J. D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 2001, 65, 1-52.
11. Corbin, J. D.; Francis, S. H. Pharmacology of phospho diesterase-5 inhibitors. Int. J. Clin. Pract. 2002, 56, 453-459.
12. Rotella, D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discovery 2002, 1, 674-682.
13. Conti, M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol. Endocrinol. 2000, 14, 1317-1327.
14. Mehats, C.; Andersen, C. B.; Filopanti, M.; Jin, S. L.; Conti, M. Cyclic nucleotide phosphodiesterases and their role in endo crine cell signaling. Trends Endocrinol. Metab. 2002, 13, 29-35.
15. Corbin, J. D.; Francis, S. H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 1999, 274, 13729-13732.
16. Ballard, S. A.; Gingell, C. J.; Tang, K.; Turner, L. A.; Price, M. E.; Naylor, A. M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 1998, 159, 2164-2171.
17. Haning, H.; Niewohner, U.; Schenke, T.; Es-Sayed, M.; Schmidt, G.; Lampe, T.; Bischoff, E. Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 865-868.
18. Porst, H. IC351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res. 2002, 14, S57-S64.
19. Card, G. L.; England, B. P.; Suzuki, Y.; Fong, D.; Powell, B.; Lee, B.; Luu, C.; Tabrizizad, M.; Gillette, S.; Ibrahim, P. N.; Artis, D. R.; Bollag, G.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y. J. Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. Structure 2004, 12, 2233-2247.
20. Gitto, R.; Ficarra, R.; Stancanelli, R.; Guardo, M.; De Luca, L.; Barreca, M. L.; Pagano, B.; Rotondo, A.; Bruno, G.; Russo, E.; De Sarroc, G.; Chimirri, G. A. Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(40-chlorophenyl)-6,7-dimethoxy-1,2,3, 4-tetrahydroisoquinoline AMPAR antagonists. Bioorg. Med. Chem. 2007, 15, 5417-5423.
21. Shaikh, A. R.; Ismael, M.; Carpio, C. A. D.; Tsuboi, H.; Koyama, M.; Endou, A.; Kubo, M.; Broclawikc, E.; Miyamoto, A. Three-dimensional quantitative structure- activity relationship (3D-QSAR) and docking studies on (benzothiazole-2-yl)acetonitrile derivatives as c-Jun N-terminal kinase-3 (JNK3) inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5917-5925.
22. Doddareddy, M. R.; Cho, Y. S.; Koh, H. Y.; Pae, A. N. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists. Bioorg. Med. Chem. 2004, 12, 3977-3985.
23. Sharma, S. K.; Kumar, G.; Kapoor, M.; Surolia, A. Combined effect of epigallo-catechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis. Biochem. Biophy. Res. Commun. 2008, 368, 12-17.
24. Liu, J.; Cui, G.; Zhao, M.; Cui, C.; Ju, J.; Peng, S. Dual-acting agents that possess reversing resistance and anticancer activities: Design, synthesis, MES-SA/Dx5 cell assay, and SAR of benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl- 1-oxo-6H-imidazo[3′,4′: 1,2]pyridin[3,4-b]indol-2- substituted acetates. Bioorg. Med. Chem. 2007, 15, 7773-7788.